

Carla M L Van Herpen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/62434/publications.pdf>

Version: 2024-02-01

94
papers

5,735
citations

136950

32
h-index

79698

73
g-index

95
all docs

95
docs citations

95
times ranked

8388
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1695-1704.	27.0	1,522
2	Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.	27.8	722
3	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871.	1.6	353
4	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2019, 20, 1124-1135.	10.7	339
5	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1221-1237.	10.7	226
6	Androgen Receptor-Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options. <i>Journal of Clinical Oncology</i> , 2011, 29, e473-e476.	1.6	164
7	A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. <i>Nature Communications</i> , 2020, 11, 728.	12.8	140
8	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. <i>International Journal of Cancer</i> , 2011, 129, 507-512.	5.1	120
9	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	2.8	108
10	Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 6152-6159.	1.6	96
11	Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. <i>Head and Neck</i> , 2018, 40, 605-613.	2.0	94
12	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. <i>Oncotarget</i> , 2016, 7, 80046-80058.	1.8	90
13	Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 446-457.	1.9	87
14	A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from the Netherlands. <i>International Journal of Cancer</i> , 2018, 143, 758-766.	5.1	81
15	Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. <i>International Journal of Cancer</i> , 2008, 123, 2354-2361.	5.1	76
16	mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. <i>International Journal of Cancer</i> , 2016, 138, 2312-2321.	5.1	76
17	Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncology</i> , The, 2019, 20, e200-e207.	10.7	68
18	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2195-2204.	2.4	61

#	ARTICLE	IF	CITATIONS
19	Phase 2 Study of Lutetium 177 ^α -Labeled Anti ^α -Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 767-770.	1.9	57
20	Theranostic applications of antibodies in oncology. <i>Molecular Oncology</i> , 2014, 8, 799-812.	4.6	53
21	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1931-1939.	6.4	53
22	Pretreatment body mass index and head and neck cancer outcome: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 328-338.	4.4	50
23	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. <i>Head and Neck</i> , 2017, 39, 140-146.	2.0	48
24	Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 723-729.	2.3	46
25	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. <i>Drug Discovery Today</i> , 2016, 21, 962-976.	6.4	46
26	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2753-2762.	7.0	42
27	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. <i>Clinical Therapeutics</i> , 2016, 38, 2286-2299.	2.5	42
28	Advances and challenges in precision medicine in salivary gland cancer. <i>Cancer Treatment Reviews</i> , 2019, 80, 101906.	7.7	38
29	Temsirolimus for metastatic desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1431-1432.	1.5	36
30	Intestinal ^α -type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. <i>Head and Neck</i> , 2016, 38, 1564-1570.	2.0	35
31	Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. <i>Oral Oncology</i> , 2017, 72, 198-200.	1.5	35
32	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue ^α -tested <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32
33	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring <i>BRAF</i> V600 or <i>NRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8511-8511.	1.6	32
34	Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. <i>Molecular Pharmaceutics</i> , 2017, 14, 2147-2157.	4.6	28
35	Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer. <i>Head and Neck</i> , 2019, 41, 3187-3200.	2.0	28
36	Normalcy of food intake in patients with head and neck cancer supported by combined dietary counseling and swallowing therapy: A randomized clinical trial. <i>Head and Neck</i> , 2016, 38, E198-206.	2.0	27

#	ARTICLE	IF	CITATIONS
37	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<sc>DIET</sc> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	4.7	26
38	Merkel Cell Carcinoma: New Trends. <i>Cancers</i> , 2021, 13, 1614.	3.7	25
39	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. <i>Clinical Cancer Research</i> , 2022, 28, 1402-1411.	7.0	24
40	Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer. <i>Cancer</i> , 2020, 126, 3982-3990.	4.1	22
41	Phase I Study of Afatinib and Selumetinib in Patients with <i>KRAS</i>-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. <i>Oncologist</i> , 2021, 26, 290-e545.	3.7	21
42	Caregiversâ€™ burden and fatigue during and after patientsâ€™ treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study. <i>Supportive Care in Cancer</i> , 2019, 27, 4145-4154.	2.2	20
43	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 651-658.	3.5	20
44	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2593.	1.6	20
45	Degree of nephrotoxicity after intermediateâ€or highâ€dose cisplatinâ€based chemoradiotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2016, 38, E1575-81.	2.0	19
46	Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. <i>Head and Neck</i> , 2016, 38, E559-65.	2.0	19
47	Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments. <i>Neoplasia</i> , 2014, 16, 221-228.	5.3	18
48	Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 455-464.	1.6	18
49	The relationship between sunitinib exposure and both efficacy and toxicity in realâ€world patients with renal cell carcinoma and gastrointestinal stromal tumour. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 326-335.	2.4	18
50	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i>-mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3002-3010.	7.0	18
51	Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1935557.	4.6	17
52	Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. <i>Acta OncolÃ³gica</i> , 2017, 56, 1238-1240.	1.8	16
53	Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. <i>British Journal of Cancer</i> , 2019, 121, 34-36.	6.4	16
54	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanoma. <i>Oncotarget</i> , 2019, 10, 1850-1859.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Unmet supportive care needs of patients with rare cancer: A systematic review. <i>European Journal of Cancer Care</i> , 2021, 30, e13502.	1.5	16
56	Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 249.	2.7	15
57	Experiences of bereaved family caregivers with shared decision making in palliative cancer treatment: a qualitative interview study. <i>BMC Palliative Care</i> , 2021, 20, 137.	1.8	14
58	Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase II randomized phase II study Commence. <i>Head and Neck</i> , 2020, 42, 828-838.	2.0	12
59	Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer. <i>European Journal of Cancer</i> , 2022, 161, 128-137.	2.8	12
60	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , 2019, 14, 441-451.	3.6	11
61	Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11
62	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
63	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021, 13, 3527.	3.7	10
64	A phase I study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. <i>Investigational New Drugs</i> , 2018, 36, 828-835.	2.6	8
65	Toxicity-induced modification of treatment: what is in a name?. <i>European Journal of Cancer</i> , 2018, 104, 145-150.	2.8	8
66	Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. <i>International Journal of Cancer</i> , 2022, 150, 308-316.	5.1	8
67	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021, 148, 2799-2806.	5.1	8
68	Salivary duct carcinoma: Clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease (n=31) Study of the Dutch head and neck society (DHNS). <i>Journal of Clinical Oncology</i> , 2016, 34, 6016-6016.	1.6	8
69	Informal caregiver well-being during and after patients' treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study. <i>Supportive Care in Cancer</i> , 2021, 29, 2481-2491.	2.2	7
70	Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 252-252.	1.6	7
71	Caution for interstitial lung disease as a cause of CA 15 rise in advanced breast cancer patients treated with everolimus. <i>International Journal of Cancer</i> , 2014, 135, 1007-1007.	5.1	6
72	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. <i>Acta Oncologica</i> , 2016, 55, 444-448.	1.8	6

#	ARTICLE	IF	CITATIONS
73	Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. <i>Head and Neck</i> , 2019, 41, 488-494.	2.0	6
74	The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 768-772.	2.4	5
75	Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1233-1242.	2.2	5
76	Thermal distribution, physiological effects and toxicities of extracorporeally induced whole-body hyperthermia in a pig model. <i>Physiological Reports</i> , 2020, 8, e14366.	1.7	5
77	How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death. <i>Palliative and Supportive Care</i> , 2016, 14, 241-249.	1.0	4
78	Low-grade salivary duct carcinoma in the bronchus. <i>Histopathology</i> , 2016, 68, 758-760.	2.9	4
79	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. <i>Oral Oncology</i> , 2020, 110, 105018.	1.5	4
80	Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e042404.	1.9	3
81	Food intervention to make therapy with pazopanib more patient-friendly and affordable. <i>Journal of Clinical Oncology</i> , 2016, 34, 11040-11040.	1.6	3
82	Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1. <i>Anticancer Research</i> , 2005, 25, 1015-21.	1.1	3
83	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1634-1640.	3.3	2
84	Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy. <i>Oncotarget</i> , 2019, 10, 3833-3834.	1.8	2
85	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2015, 35, 5601-6.	1.1	2
86	A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 5061-5061.	1.6	1
87	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2565-2565.	1.6	1
88	Prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC). <i>Journal of Clinical Oncology</i> , 2016, 34, 6079-6079.	1.6	1
89	Results of histopathological revisions of major salivary gland neoplasms in routine clinical practice. <i>Journal of Clinical Pathology</i> , 2023, 76, 374-378.	2.0	1
90	Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e290.	10.7	0

#	ARTICLE	IF	CITATIONS
91	Case Report: Two Cases of Salivary Duct Carcinoma in Workers With a History of Chromate Exposure. <i>Frontiers in Medicine</i> , 2021, 8, 730403.	2.6	0
92	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9070-9070.	1.6	0
93	Prognostic factors for overall survival of patients with head and neck soft tissue sarcoma based on 25 years data from the Netherlands Cancer registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6050-6050.	1.6	0
94	The complexity of sunitinib dosing in renal cell cancer patients. <i>Translational Andrology and Urology</i> , 2012, 1, 194-6.	1.4	0